Inhibitor of metadherin expression
AssigneesSecarna Pharmaceuticals GmbH & Co. KG, Firebrand Therapeutics, Inc.
InventorsFrank JASCHINSKI, Richard KLAR, Sven MICHEL, John Fenyu JIN
Life of this patent
Estimating the term…
Abstract
The present invention refers to an inhibitor consisting of an oligonucleotide comprising 12 to 25 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of MTDH of SEQ ID NO.1 (human mRNA), SEQ ID NO.2 (human pre-mRNA), SEQ ID NO.223 (mouse mRNA) and/or SEQ ID NO.224 (mouse pre-mRNA), wherein the oligonucleotide inhibits at least 50% of the MTDH expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
Claims12
MTDH inhibitor consisting of an antisense oligonucleotide comprising 12 to 25 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of MTDH of SEQ ID NO.1, of SEQ ID NO.2 or a combination thereof, wherein the oligonucleotide inhibits at least 50% of the MTDH expression compared to an untreated control.
A method of preventing and/or treating a disorder, where an MTDH imbalance is involved, comprising administering the inhibitor of claim 1 to a subject in need thereof.
The method according to claim 9, wherein the disorder is a malignant or benign tumor or a kidney disease.
The method according to claim 9, wherein the inhibitor or the composition is administered locally or systemically.
Dependencies are inferred from the claim text.